(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.60%) $83.35
(-1.16%) $1.619
(0.01%) $2 347.50
(0.89%) $27.50
(0.26%) $924.50
(-0.06%) $0.934
(-0.04%) $11.02
(-0.09%) $0.800
(0.00%) $92.17
-0.73% INR 655.00
Live Chart Being Loaded With Signals
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates in three segments: Diagnostic Testing Services, Imaging Services, and Others...
Stats | |
---|---|
Tagesvolumen | 48 906.00 |
Durchschnittsvolumen | 114 366 |
Marktkapitalisierung | 34.68B |
EPS | INR0 ( 2024-02-01 ) |
Nächstes Ertragsdatum | ( INR0 ) 2024-05-21 |
Last Dividend | INR18.00 ( 2023-04-20 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 53.47 |
ATR14 | INR0.648 (0.10%) |
Volumen Korrelation
Thyrocare Technologies Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Thyrocare Technologies Korrelation - Währung/Rohstoff
Thyrocare Technologies Finanzdaten
Annual | 2022 |
Umsatz: | INR5.27B |
Bruttogewinn: | INR3.63B (69.01 %) |
EPS: | INR12.16 |
FY | 2022 |
Umsatz: | INR5.27B |
Bruttogewinn: | INR3.63B (69.01 %) |
EPS: | INR12.16 |
FY | 2022 |
Umsatz: | INR5.89B |
Bruttogewinn: | INR4.19B (71.18 %) |
EPS: | INR33.30 |
FY | 2021 |
Umsatz: | INR4.95B |
Bruttogewinn: | INR3.31B (66.86 %) |
EPS: | INR21.41 |
Financial Reports:
No articles found.
Thyrocare Technologies Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR18.00 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR2.50 | 2016-09-01 |
Last Dividend | INR18.00 | 2023-04-20 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 11 | -- |
Total Paid Out | INR105.50 | -- |
Avg. Dividend % Per Year | 1.39% | -- |
Score | 2.33 | -- |
Div. Sustainability Score | 2.68 | |
Div.Growth Potential Score | 5.08 | |
Div. Directional Score | 3.88 | -- |
Year | Amount | Yield |
---|---|---|
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR10.00 | 1.55% |
2019 | INR25.00 | 4.64% |
2020 | INR10.00 | 1.85% |
2021 | INR15.00 | 1.60% |
2022 | INR15.00 | 1.35% |
2023 | INR18.00 | 2.94% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
POONAWALLA.NS | Dividend Junior | 2023-07-18 | Sporadic | 21 | 0.21% | |
JTLIND.NS | Dividend Junior | 2023-08-04 | Insufficient data to determine frequency | 2 | 0.04% | |
DPABHUSHAN.NS | Dividend Junior | 2023-09-22 | Annually | 3 | 0.15% | |
ABBOTINDIA.NS | Dividend Junior | 2023-07-20 | Annually | 17 | 0.52% | |
SPIC.NS | Dividend Junior | 2023-09-20 | Annually | 3 | 0.70% | |
MPHASIS.NS | Dividend Knight | 2023-07-05 | Annually | 20 | 1.43% | |
HESTERBIO.NS | Dividend Junior | 2023-09-13 | Annually | 10 | 0.31% | |
BIRLACABLE.NS | Dividend Junior | 2023-09-04 | Sporadic | 11 | 0.93% | |
RAYMOND.NS | Dividend Junior | 2023-06-23 | Sporadic | 29 | 0.15% | |
KOTARISUG.NS | Dividend Junior | 2023-08-03 | Sporadic | 11 | 0.58% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.118 | 1.500 | 7.63 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.128 | 1.500 | 9.69 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 24.85 | 1.000 | 1.909 | 1.909 | [3 - 30] |
operatingCashFlowPerShareTTM | 16.82 | 2.00 | 4.39 | 8.79 | [0 - 30] |
freeCashFlowPerShareTTM | 16.82 | 2.00 | 1.590 | 3.18 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.708 | 1.000 | 1.541 | 1.541 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.168 | 1.000 | 8.63 | 8.63 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 2.68 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 52.98 | 1.000 | 4.75 | 0 | [1 - 100] |
returnOnEquityTTM | 0.128 | 2.50 | 9.80 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 16.82 | 2.00 | 4.39 | 3.18 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 16.82 | 2.00 | 4.39 | 8.79 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.954 | 1.500 | 6.97 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.161 | 1.000 | 8.48 | 0 | [0.1 - 0.5] |
Total Score | 5.08 |
Thyrocare Technologies
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates in three segments: Diagnostic Testing Services, Imaging Services, and Others. The company conducts various medical diagnostic tests and profiles of tests that focuses on early detection and management of disorders and diseases, including thyroid, growth, metabolism, auto-immunity, diabetes, anaemia, cardiovascular, infertility, COVID, and various infectious diseases. Its profiles of tests include 34 profiles of tests administered under its Aarogyam brand, which offers patients a suite of wellness and preventive health care tests. The company also sells glucometer and glucostrips under the brand name Sugarscan; consumables; and radiopharmaceutical. Thyrocare Technologies Limited was founded in 1996 and is based in Navi Mumbai, India. Thyrocare Technologies Limited is a subsidiary of Docon Technologies Private Limited.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.